8:00 am Coffee & Registration
NAVIGATING NEXT-GENERATION ONCOLOGY MODELS: FROM MODELLING TUMOR MICROENVIRONMENT TO INTERROGATING MOA
8:25 am Chairs’ Opening Remarks
8:30 am Optimizing IO Preclinical Research: GEMMs, CDX, PDX, Humanized Mouse Models or Organoids?
Synopsis
- Highlighting the key attributes of each model in the context of their specific research questions
- Strengthening linkages between preclinical and clinical development
- Maximizing current models while identifying appropriate prognostic and predictive biomarkers
9:00 am Presentation by Tempus
9:30 am Development of Image-based In vitro/In vivo Platform for Targeting CAFs
Synopsis
- Developing Image-based in vitro co-culture system to recapitulate the multicellular elements of TME, this allows monitoring of key cell-cell interactions between cancer cells, immune cells, and CAFs
- Developing multiple panels IVIS to better understand MOA of novel immune therapies
- Addressing the importance of using the right tumor cell line for investigating TME
10:00 am Presentation by Kiyatec
10:30 am Speed Networking
Synopsis
Join our speed networking session tailored for preclinical and translational experts, like yourselves, to connect with industry peers & facilitating rapid yet meaningful exchanges of insights & expertise.
11:00 am Morning Break & Networking
Applications in Drug Discovery & Screening
Track Moderator: Hongyu Xue, Director, In Vivo Pharmacology, Bayer
11:30 am Optimizing Patient Representation Using PDX Models
Synopsis
- Addressing the ways to identify the best PDX models to use
- Understanding how to group PDX models
- Can fibrotic elements, extracellular matrix, and stroma be replicated using PDX models?
12:00 pm Roundtable: Increasing Clinical Translatability by Maximizing the Use of GEMMS
Synopsis
- Better recapitulating the genotype and phenotype of the disease with transgenic models
- Illustrating novel efficacy and safety data to evaluate the predictivity of using GEMMS
Applications for Efficacy Evaluation & Biomarker Discovery
Track Moderator: Regina Reilly, Research Fellow, AbbVie
11:30 am In Vivo Imaging Biomarkers for Tumor Model Development & Understanding Mode of Action
Synopsis
- Preclinical imaging to understand tumor growth in orthotopic and GEMM models
- Development of bioluminescence reporter mouse models for visualizing and quantifying immune cells in vivo
- Clinically translatable imaging biomarkers in preclinical tumor models to understand mode of action
12:00 pm Presentation by Mission Bio
12:30 pm Lunch Break & Networking
1:30 pm Effectively Replicating the Tumor Stroma & Fibroblasts Using in vivo & in vitro Models
Synopsis
- Spotlighting advances in successfully mimicking the tumor stroma
- Reimagining drug discovery by recapitulating essential elements in tumor development
- How could we develop a model to address hypoxia?
2:00 pm Presentation by Chem Partner
1:30 pm Unlocking the Potential of Leveraging Cell Lines to Identify Patient Populations & Discover Optimal Biomarkers
Synopsis
- Research the range of cell lines available to overcome current limitations
- Using evaluation models that have high expression Identifying a patient population regardless of histotype
2:00 pm Presentation by TD2
2:30 pm Afternoon Break & Networking
PITTING IN VITRO VS IN VIVO MODELLING TO INVESTIGATE CASE STUDIES IN IMPROVING TRANSLATABILITY
3:00 pm How Can Physiologically Relevant 3D Tissue Models Be More Predictive of the Tumor Microenvironment?
Synopsis
- Assessing the role of the extracellular matrix and its importance in modeling the tumor microenvironment (TME)
- Enhancing spheroid stromal complexity using “MatriSpheres” to mimic tumor morphology and physical barriers within the TME
- Capturing tumor heterogeneity in vitro that reflects transcriptomic phenotypes of in vivo cancer cells
3:30 pm Presentation by Certis
4:00 pm Panel Discussion: Evaluating Animal Models & Their Benefits in Testing Clinical Agents
Synopsis
- When should we still use mice in testing?
- The use of dogs for effectively demonstrating efficacy, toxicity, and impact from a clinical agent
- Leveraging monkeys for toxicity studies
- Delving into tissue cross-reactivity
4:30 pm Presentation by Xenostart
5:00 pm Chair’s Closing Remarks
5:10 pm Tumor Models Poster Session
Synopsis
This Poster Session is your go-to session to obtain competitive insights, deeply connect with your peers and present your most innovative work.